• 

  Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer

  Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer

Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer

[email protected]2023-12-19T03:41:39-06:00

Read More

Comments Off on Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer

• 

  Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke

  Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke

Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke

[email protected]2023-12-04T17:18:01-06:00

Read More

Comments Off on Dual activities of the anti-cancer drug candidate PBI-05204 provide neuroprotection in brain slice models for neurodegenerative diseases and stroke

• 

  PBI is pleased to announce an excellent rate of accrual of advanced pancreatic cancer patients to their Phase II clinical study.

  PBI is pleased to announce an excellent rate of accrual of advanced pancreatic cancer patients to their Phase II clinical study.

PBI is pleased to announce an excellent rate of accrual of advanced pancreatic cancer patients to their Phase II clinical study.

[email protected]2023-12-04T17:18:06-06:00

Read More

Comments Off on PBI is pleased to announce an excellent rate of accrual of advanced pancreatic cancer patients to their Phase II clinical study.

• 

  Research with colleagues at Duke University continues to reveal important brain mediated benefits in response to PBI-05204.

  Research with colleagues at Duke University continues to reveal important brain mediated benefits in response to PBI-05204.

Research with colleagues at Duke University continues to reveal important brain mediated benefits in response to PBI-05204.

[email protected]2023-12-04T17:18:11-06:00

Read More

Comments Off on Research with colleagues at Duke University continues to reveal important brain mediated benefits in response to PBI-05204.

• 

  NIH has expressed an interest in exploring the potential of PBI-05204 to alleviate the extreme fatigue often associated in cancer patients undergoing radiation therapy.

  NIH has expressed an interest in exploring the potential of PBI-05204 to alleviate the extreme fatigue often associated in cancer patients undergoing radiation therapy.

NIH has expressed an interest in exploring the potential of PBI-05204 to alleviate the extreme fatigue often associated in cancer patients undergoing radiation therapy.

[email protected]2023-12-04T17:18:15-06:00

Read More

Comments Off on NIH has expressed an interest in exploring the potential of PBI-05204 to alleviate the extreme fatigue often associated in cancer patients undergoing radiation therapy.

• 

  Antioxidant, anti-inflammatory, anti-apoptotic, and skin regenerative properties of an Aloe vera-based extract of Nerium oleander leaves

  Antioxidant, anti-inflammatory, anti-apoptotic, and skin regenerative properties of an Aloe vera-based extract of Nerium oleander leaves

Antioxidant, anti-inflammatory, anti-apoptotic, and skin regenerative properties of an Aloe vera-based extract of Nerium oleander leaves

[email protected]2024-01-24T13:48:55-06:00

Read More

Comments Off on Antioxidant, anti-inflammatory, anti-apoptotic, and skin regenerative properties of an Aloe vera-based extract of Nerium oleander leaves

• 

  In late December, 2014 the FDA approved of our plans to take PBI-05204 forward into clinical Phase II trials.

  In late December, 2014 the FDA approved of our plans to take PBI-05204 forward into clinical Phase II trials.

In late December, 2014 the FDA approved of our plans to take PBI-05204 forward into clinical Phase II trials.

[email protected]2023-12-04T17:18:19-06:00

Read More

Comments Off on In late December, 2014 the FDA approved of our plans to take PBI-05204 forward into clinical Phase II trials.

• 

  A manuscript describing the therapeutic effects of PBI-05204 against human pancreatic cancer implanted orthotopically (within the pancreas) in immunocompromised mice has been accepted for publication in Investigational New Drugs

  A manuscript describing the therapeutic effects of PBI-05204 against human pancreatic cancer implanted orthotopically (within the pancreas) in immunocompromised mice has been accepted for publication in Investigational New Drugs

A manuscript describing the therapeutic effects of PBI-05204 against human pancreatic cancer implanted orthotopically (within the pancreas) in immunocompromised mice has been accepted for publication in Investigational New Drugs

[email protected]2023-12-04T17:18:25-06:00

Read More

Comments Off on A manuscript describing the therapeutic effects of PBI-05204 against human pancreatic cancer implanted orthotopically (within the pancreas) in immunocompromised mice has been accepted for publication in Investigational New Drugs

• 

  A manuscript describing the results of the Phase I trial of PBI-05204 conducted at the Univ. Texas M. D. Anderson Cancer Center has been published in Investigational New Drugs.

  A manuscript describing the results of the Phase I trial of PBI-05204 conducted at the Univ. Texas M. D. Anderson Cancer Center has been published in Investigational New Drugs.

A manuscript describing the results of the Phase I trial of PBI-05204 conducted at the Univ. Texas M. D. Anderson Cancer Center has been published in Investigational New Drugs.

[email protected]2023-12-04T17:18:31-06:00

Read More

Comments Off on A manuscript describing the results of the Phase I trial of PBI-05204 conducted at the Univ. Texas M. D. Anderson Cancer Center has been published in Investigational New Drugs.

• 

  Additional testing of PBI-05204 against patient derived tumors is being conducted at Rational Therapeutics (San Diego, CA).

  Additional testing of PBI-05204 against patient derived tumors is being conducted at Rational Therapeutics (San Diego, CA).

Additional testing of PBI-05204 against patient derived tumors is being conducted at Rational Therapeutics (San Diego, CA).

[email protected]2023-12-04T17:18:38-06:00

Read More

Comments Off on Additional testing of PBI-05204 against patient derived tumors is being conducted at Rational Therapeutics (San Diego, CA).